ArticleOncogene2021
Hormonal modulation of ESR1 mutant metastasis.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 42 citations in OpenAlex.
- ESR1 mutations are associated with enhanced MTORC1 signaling in a context-dependent manner.Communications biology · 2026Article
- Identification and Validation of the ESR1 Y537S Mutant-Enriched Enhancer and Its Downstream Target IGFBP3.Cancer research communications · 2026Article
- PSMB8: an immune-related prognostic marker for low-grade gliomas.Translational cancer research · 2026Article
- Estrogen Receptors and Enzymes Involved in Estrogen Synthesis as Breast Cancer Treatment Targets.International journal of molecular sciences · 2026Review
- Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.Cancer research · 2026Article
- Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion.JCI insight · 2026Article
- Causality between immune cells and HER2-breast cancer: A 2‑sample Mendelian randomization study.Medicine · 2026Article
- Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions.Discover oncology · 2025Review
- Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries.NPJ breast cancer · 2025Article
- ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Identification of Isovitexin as a novel CYP17A1 inhibitor through virtual screening and evaluation of its anti-cancer effects in MCF-7 breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Combining network pharmacology and molecular docking to explore the pharmacological mechanism of Codonopsis Radix.-Hedysarum Multijugum Maxim.-Atractylodes Macrocephala Koidz. in treating lung cancer.BMC complementary medicine and therapies · 2025Article
- Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours.Communications biology · 2025Article
- Transcription factors and hormone receptors: Sex‑specific targets for cancer therapy (Review).Oncology letters · 2025Review
- Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells.Breast cancer research : BCR · 2025Article
- Evidence that CRISPR-Cas9 Y537S-mutant expressing breast cancer cells activate Yes-associated protein 1 to driving the conversion of normal fibroblasts into cancer-associated fibroblasts.Cell communication and signaling : CCS · 2024Article
- Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.NPJ breast cancer · 2024Article
- Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537SResearch square · 2024Article
- Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537SbioRxiv : the preprint server for biology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
31 authors at 7 institutions in 2 countries.
Guowei GuLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Lin TianCancer Biology & Genetics Program Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3661-4453
Sarah K HerzogLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Yassine RechoumLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Luca GelsominoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Meng GaoDepartment of Systems Biology, MD Anderson Cancer Center, Houston, TX, USA.
Lili DuDepartment of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jin-Ah KimLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Derek DustinLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Hin Ching LoLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Amanda R BeyerLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
David G EdwardsLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Thomas GonzalezLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Anna TsimelzonLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Helen J HuangDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Natalie M FernandezDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
Sandra L GrimmDan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Susan G HilsenbeckLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Dan LiuDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
Jun XuDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
Alyssa AlanizLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Shunqiang LiDepartment of Internal Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Gordon B MillsDepartment of Cell, Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-0144-9614
Filip JankuDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8123-4065
Ralf KittlerEugene McDermott Center for Human Growth and Development and Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX, USA.
Xiang H-F ZhangLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5674-8670
Cristian CoarfaDan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4183-4939
Charles E FouldsDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4908-1473
W Fraser SymmansDepartment of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1526-184X
Sebastiano AndòDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.ORCID http://orcid.org/0000-0002-5412-7045
Suzanne A W FuquaLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA. sfuqua@bcm.edu.ORCID http://orcid.org/0000-0001-8886-5161
Baylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · USUniversity of Calabria · ITMemorial Sloan Kettering Cancer Center · USOregon Health & Science University · USSouthwestern Medical CenterWashington University in St. Louis · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MProject 5: Pyolytic conversion of PAHs in contaminated sediments into char to eliminate toxicity and enhance soil fertilityP42ES027725 · NIEHS · BAYLOR COLLEGE OF MEDICINE · PI BHAGAVATULA MOORTHY · 2020 to 2026
$17.8MTranslational Research Support CoreP30ES030285 · NIEHS · BAYLOR COLLEGE OF MEDICINE · PI Cheryl L. Walker · 2019 to 2026
$14.7MWashington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft ModelsU54CA224083 · NCI · WASHINGTON UNIVERSITY · PI Brian Andrew Van Tine · 2017 to 2026
$13.0MTRAINING PROGRAM IN CELL AND MOLECULAR BIOLOGYT32GM008231 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI NELSON, DAVID LOREN · 1990 to 2019
$7.2MReplication Stress and DNA Damage Response Drives ESR1 Mutant MetastasisR01CA072038 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI Suzanne AW Fuqua · 1996 to 2026
$6.7MIntegrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6MMECHANISMS OF AR-ER COLLABORATION IN HORMONE RESISTANCE AND METASTASIS OF BREAST CANCERR01CA207270 · NCI · BAYLOR COLLEGE OF MEDICINE · PI FUQUA, SUZANNE AW · 2017 to 2021
$1.8MTranslational Breast Cancer Research Training ProgramT32CA203690 · NCI · BAYLOR COLLEGE OF MEDICINE · PI FUQUA, SUZANNE AW, RIMAWI, MOTHAFFAR FAHED · 2018 to 2022
$1.0MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA072038NCI NIH HHS R01 CA207270NCI NIH HHS T32 CA203690NCI NIH HHS U01 CA217842NCI NIH HHS U54 CA224083NIEHS NIH HHS P30 ES030285NIEHS NIH HHS P42 ES027725NIGMS NIH HHS T32 GM008231
Abstract
Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 Y537S mutation induced an epithelial-mesenchymal transition (EMT) with cells exhibiting enhanced migration and invasion potential in vitro. When small subpopulations of Y537S ESR1 mutant cells were injected along with WT parental cells, tumor growth was enhanced with mutant cells becoming the predominant population in distant metastases. Y537S mutant primary xenograft tumors were resistant to the antiestrogen tamoxifen (Tam) as well as to estradiol (E
Indexed as
AnimalsAromatase InhibitorsBreast NeoplasmsCell Line, TumorDihydrotestosteroneEstradiolEstrogen Receptor alphaEstrogensFemaleGene Expression Regulation, NeoplasticHumansMiceMutationNeoplasm MetastasisReceptors, AndrogenTamoxifenAromatase InhibitorsAR protein, humanDihydrotestosteroneESR1 protein, humanEstradiolEstrogen Receptor alphaEstrogensReceptors, AndrogenTamoxifen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.